TherapeuticsMD, Inc. (TXMD)
1.90
-0.03
(-1.55%)
USD |
NASDAQ |
Oct 16, 16:00
1.90
0.00 (0.00%)
After-Hours: 20:00
TherapeuticsMD Enterprise Value : 18.36M for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 18.36M |
| October 15, 2026 | 18.71M |
| October 14, 2026 | 19.17M |
| October 13, 2026 | 19.06M |
| October 12, 2026 | 19.75M |
| October 09, 2026 | 20.21M |
| October 08, 2026 | 19.63M |
| October 07, 2026 | 19.52M |
| October 06, 2026 | 19.75M |
| October 05, 2026 | 19.63M |
| October 02, 2026 | 20.10M |
| October 01, 2026 | 19.87M |
| September 30, 2026 | 19.87M |
| September 29, 2026 | 19.98M |
| September 28, 2026 | 20.56M |
| September 25, 2026 | 20.10M |
| September 24, 2026 | 21.02M |
| September 23, 2026 | 21.49M |
| September 22, 2026 | 21.37M |
| September 21, 2026 | 20.68M |
| September 18, 2026 | 21.72M |
| September 17, 2026 | 21.60M |
| September 16, 2026 | 21.60M |
| September 15, 2026 | 21.37M |
| September 14, 2026 | 21.37M |
| Date | Value |
|---|---|
| September 11, 2026 | 21.37M |
| September 10, 2026 | 20.68M |
| September 09, 2026 | 20.91M |
| September 08, 2026 | 21.14M |
| September 04, 2026 | 21.95M |
| September 03, 2026 | 22.30M |
| September 02, 2026 | 22.53M |
| September 01, 2026 | 21.49M |
| August 31, 2026 | 21.60M |
| August 28, 2026 | 22.07M |
| August 27, 2026 | 22.07M |
| August 26, 2026 | 22.76M |
| August 25, 2026 | 22.76M |
| August 24, 2026 | 20.33M |
| August 21, 2026 | 20.21M |
| August 20, 2026 | 20.21M |
| August 19, 2026 | 19.87M |
| August 18, 2026 | 19.63M |
| August 17, 2026 | 19.63M |
| August 14, 2026 | 20.33M |
| August 13, 2026 | 20.44M |
| August 12, 2026 | 20.44M |
| August 11, 2026 | 20.33M |
| August 10, 2026 | 20.33M |
| August 07, 2026 | 20.33M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.895B |
| Corcept Therapeutics, Inc. | 11.59B |
| Veru, Inc. | 16.11M |
| Johnson & Johnson | 643.72B |
| Eli Lilly & Co. | 1.229T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.164M |
| Revenue (Quarterly) | 0.869M |
| Total Expenses (Quarterly) | 0.705M |
| EPS Diluted (Quarterly) | 0.0133 |
| Gross Profit Margin (Quarterly) | 62.14% |
| Profit Margin (Quarterly) | 18.87% |
| Earnings Yield | -0.99% |
| Normalized Earnings Yield | -0.6737 |